Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

iBio (IBIO) Cash & Equivalents (2016 - 2025)

iBio (IBIO) has disclosed Cash & Equivalents for 16 consecutive years, with $28.7 million as the latest value for Q4 2025.

  • On a quarterly basis, Cash & Equivalents rose 310.0% to $28.7 million in Q4 2025 year-over-year; TTM through Dec 2025 was $28.7 million, a 310.0% increase, with the full-year FY2025 number at $8.6 million, down 39.61% from a year prior.
  • Cash & Equivalents was $28.7 million for Q4 2025 at iBio, up from $28.1 million in the prior quarter.
  • In the past five years, Cash & Equivalents ranged from a high of $84.6 million in Q1 2021 to a low of $1.5 million in Q3 2023.
  • A 5-year average of $22.9 million and a median of $10.5 million in 2022 define the central range for Cash & Equivalents.
  • Peak YoY movement for Cash & Equivalents: surged 742.9% in 2021, then tumbled 90.57% in 2022.
  • iBio's Cash & Equivalents stood at $39.2 million in 2021, then plummeted by 90.57% to $3.7 million in 2022, then fell by 24.57% to $2.8 million in 2023, then surged by 151.08% to $7.0 million in 2024, then soared by 310.0% to $28.7 million in 2025.
  • Per Business Quant, the three most recent readings for IBIO's Cash & Equivalents are $28.7 million (Q4 2025), $28.1 million (Q3 2025), and $8.6 million (Q2 2025).